GEN Exclusives

More »

GEN News Highlights

Back to Item »

Two Phase III Studies Confirm Benefits of Pfizer’s Tofacitinib Against Active RA

Oral JAK inhibitor reduced signs and symptoms of disease in patients responding inadequately to either methotrexate or a TNF inhibitor.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?